Overview

A Study of Trastuzumab-MCC-DM1 Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer Who Have Previously Received a Trastuzumab-Containing Regimen

Status:
Completed

Trial end date:
2009-06-01

Target enrollment:

Participant gender:

Summary

This is a phase I, multicenter, open-label, dose-escalation study of single-agent trastuzumab-MCC-DM1 administered by intravenous (IV) infusion in patients with HER2-positive metastatic breast cancer (MBC) who have previously received trastuzumab. The study will assess the safety, tolerability, and pharmacokinetics of trastuzumab-MCC-DM1 and determine the dose and schedule to be used in Phase II.

Phase:

Phase 1

Details

Lead Sponsor:

Genentech, Inc.

Treatments:

Ado-Trastuzumab Emtansine
Maytansine
Trastuzumab